Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.

Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.